Recombinant Listeria monocytogenes cancer vaccines.
Listeria monocytogenes has recently been exploited as a vector for targeting antigens to the immune system. In the past year it has been shown to be particularly effective as a tumor antigen vector. Here we set its potency as a cancer vaccine in the context of the type of immunity induced by this facultative intracellular bacterium.
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA. yvonne@mail.med.upenn.edu
Y
Y
Paterson
G
G
Ikonomidis
D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000235:genetics; D019496:Cancer Vaccines / Q000302:isolation & purification*; D016207:Cytokines / Q000276:immunology; D005822:Genetic Vectors; D007371:Interferon-gamma / Q000276:immunology; D007375:Interleukin-1 / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D008089:Listeria monocytogenes / Q000235:genetics / Q000276:immunology*; D008088:Listeriosis / Q000276:immunology; D051379:Mice; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D007371:Interferon-gamma